赛托生物(300583) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was CNY 334,785,915.82, representing a 31.99% increase compared to CNY 253,646,857.08 in the same period last year[4] - Net profit attributable to shareholders for Q1 2023 was CNY 15,355,110.28, up 20.53% from CNY 12,739,991.21 in Q1 2022[4] - The company's operating profit was ¥19,947,417.76, an increase of 42% from ¥14,066,025.89 in the same period last year[26] - Net profit for Q1 2023 was ¥17,525,308.93, representing a 49% increase compared to ¥11,721,511.57 in Q1 2022[26] - Total operating revenue for Q1 2023 reached ¥334,785,915.82, a 32% increase from ¥253,646,857.08 in Q1 2022[25] - Total operating costs amounted to ¥313,685,870.45, up 31% from ¥239,159,017.57 in the previous year[25] - The company reported a total comprehensive income of ¥15,999,364.10 for Q1 2023, compared to ¥7,060,494.22 in Q1 2022[26] Cash Flow and Liquidity - The net cash flow from operating activities increased by 16.45% to CNY 10,704,060.35, compared to CNY 9,191,765.31 in the previous year[4] - The cash inflow from operating activities for Q1 2023 was CNY 248,042,987.04, a decrease of 11.7% compared to CNY 281,019,424.09 in the previous period[28] - The total cash outflow from operating activities was CNY 237,338,926.69, down from CNY 271,827,658.78 in the previous period[28] - The cash received from sales of goods and services was CNY 239,332,850.86, a decrease from CNY 243,366,071.04 in the previous period[28] - The cash paid for purchasing goods and services was CNY 92,594,498.30, an increase from CNY 48,014,507.18 in the previous period[28] - The cash paid to employees was CNY 42,219,708.05, an increase from CNY 39,952,522.80 in the previous period[28] - The net cash outflow from investing activities was CNY -27,232,006.03, an improvement from CNY -59,898,407.34 in the previous period[29] - The cash inflow from financing activities totaled CNY 381,974,721.80, up 36.4% from CNY 280,000,000.00 in the previous period[29] - The net cash flow from financing activities was CNY 6,643,103.13, a significant decrease of 87.5% compared to CNY 53,181,054.01 in the previous period[29] - The ending balance of cash and cash equivalents was CNY 46,054,445.31, down from CNY 61,832,290.63 in the previous period[29] - The company's cash and cash equivalents increased to ¥249,546,369.14 from ¥188,398,286.35 at the beginning of the year, representing a growth of 32.4%[22] Assets and Liabilities - The total assets at the end of Q1 2023 were CNY 3,107,308,236.19, a 3.75% increase from CNY 2,995,140,143.52 at the end of the previous year[4] - Total liabilities increased to ¥1,320,411,681.70, compared to ¥1,224,242,953.13 in the previous year[24] - The company’s total liabilities increased, with accounts payable rising by 43.00% to CNY 20,851.59 million due to increased payments made via bank acceptance bills[9] - Accounts receivable rose to ¥244,889,134.78 from ¥196,565,259.17, an increase of 24.6%[22] - Inventory increased to ¥635,759,362.23 from ¥608,261,782.36, reflecting a growth of 4.5%[22] - Total equity reached ¥1,786,896,554.49, slightly up from ¥1,770,897,190.39 in Q1 2022[24] Research and Development - Research and development expenses surged by 96.16% to CNY 1,399.94 million, reflecting accelerated project advancements[12] - Research and development expenses rose to ¥13,999,442.81, a significant increase of 96% from ¥7,136,868.14 in Q1 2022[25] Shareholder Information - Total number of common shareholders at the end of the reporting period is 10,821[17] - The largest shareholder, Shandong Runxin Investment Co., Ltd., holds 25.31% of shares, totaling 27,060,864 shares[17] - The company has a total of 27,154,364 shares held by major shareholders participating in financing activities[18] Regulatory and Market Activities - The company received approval from the China Securities Regulatory Commission for a stock issuance on March 29, 2023[19] - The company plans to expand its market presence following the successful registration of new shares[19] Return on Equity - The weighted average return on equity increased to 0.89% from 0.75% in the previous year[4] - The company reported a basic earnings per share of CNY 0.14, which is a 16.67% increase from CNY 0.12 in the same quarter last year[4] - Basic and diluted earnings per share for Q1 2023 were both ¥0.14, up from ¥0.12 in Q1 2022[26]